

Accepted Manuscript

Title: Population-Based Analysis of Treatment Toxicity among Men with Castration-Resistant Prostate Cancer: a Phase IV Study

Author: Christopher J.D. Wallis, Raj Satkunasivam, Refik Saskin, Symron Bansal, Girish S. Kulkarni, Urban Emmenegger, Robert K. Nam

PII: S0090-4295(17)31221-9

DOI: <https://doi.org/10.1016/j.urology.2017.08.067>

Reference: URL 20774

To appear in: *Urology*

Received date: 5-6-2017

Accepted date: 22-8-2017

Please cite this article as: Christopher J.D. Wallis, Raj Satkunasivam, Refik Saskin, Symron Bansal, Girish S. Kulkarni, Urban Emmenegger, Robert K. Nam, Population-Based Analysis of Treatment Toxicity among Men with Castration-Resistant Prostate Cancer: a Phase IV Study, *Urology* (2017), <https://doi.org/10.1016/j.urology.2017.08.067>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Population-based analysis of treatment toxicity among men with castration-resistant prostate cancer: a phase IV study

Christopher J.D. Wallis MD PhD^{1,2}, Raj Satkunasivam MD MS¹, Refik Saskin MSc³, Symron Bansal MSc³, Girish S. Kulkarni MD PhD⁴, Urban Emmenegger MD⁵, Robert K. Nam MD MSc^{1,2}

Affiliations

¹Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto

²Institute for Health Policy, Management & Evaluation, University of Toronto

³Institute of Clinical Evaluative Sciences, Sunnybrook Research Institute, University of Toronto

⁴Division of Urology, University Health Network, University of Toronto

⁵Division of Medical Oncology, Sunnybrook Health Sciences Centre, University of Toronto

Address for Correspondence:

Dr. Robert Nam

Room MG-406 2075 Bayview Ave.

Toronto, Ontario, Canada M4N 3M5

Phone: (416) 480-5075 FAX: (416) 480-6934

Email: Robert.nam@utoronto.ca

Word count **Abstract:** 220 **Manuscript body:** 2577

Text pages: 15; **Tables:** 4; **Figures:** 1; **Supplementary Tables:** 3.

Running head: Toxicity of contemporary mCRPC agents

Keywords: Prostatic neoplasms, castration-resistant; hospitalization; toxoids; Phenylthiohydantoin; Antineoplastic agents.

This study has been accepted for poster presentation at the 2017 Genitourinary Cancers Symposium and at the 2017 American Urological Association Annual Meeting.

Conflict of interest: UE declares honoraria from Astellas Pharma, Janssen Oncology, Sanofi-Genzyme Canada, and Amgen Canada. UE further declares consulting or advisor roles for Astellas Pharma, Janssen Oncology, Sanofi-Genzyme Canada, and Amgen Canada. The remaining authors declare no conflicts of interest. All authors have completed ICMJE forms.

Acknowledgement of Research support: C.J.D.W. is supported by the Canadian Institute of Health Research Banting and Best Doctoral Award. R.K.N. is supported by the Ajmera Family Chair in Urologic Oncology. The funding organization had no role in the design or conduct of the study; the collection, management, analysis and interpretation of the data; nor the preparation, review or approval of the manuscript. This study made use of de-identified data from the ICES Data Repository, which is managed by the Institute for Clinical Evaluative Sciences with support from its funders and partners: Canada's Strategy for Patient-Oriented Research (SPOR), the Ontario SPOR Support Unit, the Canadian Institutes of Health Research and the Government of Ontario. The opinions, results and conclusions reported are those of the

Download English Version:

<https://daneshyari.com/en/article/8775948>

Download Persian Version:

<https://daneshyari.com/article/8775948>

[Daneshyari.com](https://daneshyari.com)